CRME - Cardiome Pharma Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.92
+0.02 (+1.05%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.90
Open1.90
Bid1.55 x 500
Ask2.18 x 2400
Day's Range1.84 - 1.95
52 Week Range1.82 - 4.84
Volume70,784
Avg. Volume140,476
Market Cap64.24M
Beta-0.27
PE Ratio (TTM)-2.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
    Capital Cubelast month

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Aeterna Zentaris Inc. and Novelion Therapeutics Inc. (AEZS-US and NVLN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 5.75 ... Read more (Read more...)

  • What Falling Estimates & Price Mean for Cardiome (CRME)
    Zacks2 months ago

    What Falling Estimates & Price Mean for Cardiome (CRME)

    Cardiome (CRME) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
    Zacks2 months ago

    Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

    It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

  • Associated Press2 months ago

    Cardiome reports 2Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 26 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by ...

  • Cardiome's Partner SteadyMed Submits NDA for PAH Injection
    Zacks3 months ago

    Cardiome's Partner SteadyMed Submits NDA for PAH Injection

    Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).

  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
    Capital Cube5 months ago

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017

    Categories: Yahoo FinanceGet free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Aeterna Zentaris Inc. (AEZS-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 5.20 million, Net Earnings of USD -6.33 ... Read more (Read more...)

  • Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher
    Zacks5 months ago

    Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher

    Cardiome Pharma Corp. (CRME) shares rose a little above 6% in the last trading session.

  • Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
    Zacks5 months ago

    Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

    Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

  • Associated Press5 months ago

    Cardiome reports 1Q loss

    The Vancouver, British Columbia-based company said it had a loss of 20 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session
    Zacks6 months ago

    Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session

    Cardiome Pharma Corp. (CRME) shares rose over 6% in the last trading session.

  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube7 months ago

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 7.02 million, Net Earnings of USD -5.59 million. Gross margins widened from 28.73% to 61.37% compared to the same period last year, operating (EBITDA) margins now -56.11% from -136.29%. Change in operating ... Read more (Read more...)

  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
    Capital Cube7 months ago

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017

    Categories: Yahoo Finance Get free summary analysis Cardiome Pharma Corp. reports financial results for the year ended December 31, 2016. Highlights Gross margins widened from 58.09% to 63.20% compared to the same period last year, operating (EBITDA) margins now -45.80% from -95.19%. Change in operating cash flow of -0.10% compared to same period last year is about the ... Read more (Read more...)

  • Associated Press7 months ago

    Cardiome reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 18 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Is CARDIOME PHARMA CORP (CRME) a Good Stock to Buy?
    Insider Monkey10 months ago

    Is CARDIOME PHARMA CORP (CRME) a Good Stock to Buy?

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • Zackslast year

    New Strong Sell Stocks for October 26th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday